Anju’s Feasibility Flex in TA Scan Wins Best of Show at SCOPE Summit Europe

FORT LAUDERDALE, Fla., Oct. 31, 2024 /PRNewswire/ — Anju Software recently introduced Feasibility Flex, the newest feature in the flagship product, TA Scan, designed to transform clinical trial feasibility assessments. This powerful tool addresses the rising complexities of trial design and execution, providing unmatched flexibility and precision to enhance trial planning. Feasibility Flex recently won Best of Show at SCOPE Summit Europe for its innovative impact on life sciences. The award, chosen by attendees, celebrates exhibitors advancing clinical research with meaningful solutions.

Feasibility Flex allows clinical teams to input and adjust key trial parameters, ensuring more accurate enrollment projections and informed site selection. This adaptability is critical in modern trials, where fluctuating regulations, global patient recruitment challenges, and intricate protocols add layers of complexity and unpredictability. The feature harnesses TA Scan’s high quality clinical data alongside user insights, such as signature site lists and country-level start-up timelines, to deliver precision insights for strategic and operational planning.

Key capabilities of Feasibility Flex include:

  • Leveraging Data for Precision Enrollment: Build enrollment scenarios with high-quality data, enhanced by user insights, for accurate and tailored enrollment projections.
  • Dynamic Site and Country Intelligence: Fine-tune projections and site recommendations by adjusting parameters in real time. Visualize projected country-level timelines, with options to customize regulatory delay.
  • Predictability in Trial Planning: Gain comprehensive insights for informed trial planning, resulting in more efficient and predictable trials.

Feasibility Flex empowers teams to make data-driven decisions faster and with greater confidence. In an industry where only 10-12% of drugs reach the market, this feature provides an essential edge, helping organizations avoid delays, manage costs, and reduce inefficiencies.

Discover how TA Scan can transform your trial planning. Visit our website or contact our team at info@anjusoftware.com to schedule a demo today!

About Anju Software
Anju is a customer-first organization delivering adaptable life science solutions for clinical researchmedical affairs, and data science. TrialMasterIRMS MAX, and TA Scan, the company’s flagship products, lead the way in reducing complexities in the drug and device discovery and commercialization process. With a team of industry experts and a diverse suite of versatile products, Anju empowers clients to drive innovation, efficiency, and compliance. Anju is a portfolio company of Valsoft serving the worldwide pharmaceutical, biotech and contract research Life Sciences markets.

Media Contact
John F. Kouten
JFK Communications, Inc.
+1 609.241.7352
jfkouten@jfkhealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/anjus-feasibility-flex-in-ta-scan-wins-best-of-show-at-scope-summit-europe-302292973.html

SOURCE Anju Software

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

3 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

6 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

6 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

6 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

6 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

6 hours ago